What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
Sell
20
IMCR Quote, Financials, Valuation and Earnings
Last price:
$29.87
Seasonality move
:
-10.17%
Day range:
$29.46 - $30.22
52-week range:
$27.69 - $76.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.10x
P/B ratio:
3.95x
Volume:
81.2K
Avg. volume:
294.7K
1-year change:
-57.81%
Market cap:
$1.5B
Revenue:
$249.4M
EPS (TTM):
-$0.95
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IMCR
Immunocore Holdings PLC
|
$84.3M | -$0.20 | 20.13% | -50.44% | $66.54 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$8.8M | -$0.15 | 4199.24% | -9.44% | -- |
|
AUTL
Autolus Therapeutics PLC
|
$3M | -$0.24 | -61.82% | -46.14% | $10.45 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
NCNA
NuCana PLC
|
-- | -$0.09 | -- | -98.11% | $64.50 |
|
VRNA
Verona Pharma PLC
|
$16.5M | -$0.25 | -- | -2.08% | $47.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IMCR
Immunocore Holdings PLC
|
$29.86 | $66.54 | $1.5B | -- | $0.00 | 0% | 5.10x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.65 | -- | $166.1M | -- | $0.00 | 0% | 0.91x |
|
AUTL
Autolus Therapeutics PLC
|
$2.68 | $10.45 | $713.2M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$4.50 | $17.97 | $2.6M | -- | $0.00 | 0% | 4.06x |
|
NCNA
NuCana PLC
|
$1.31 | $64.50 | $5.1M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$46.59 | $47.29 | $3.8B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IMCR
Immunocore Holdings PLC
|
53.73% | -0.270 | 28.17% | 3.62x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 4.431 | 20.51% | 3.54x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.664 | -- | 17.97x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.100 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | 1.546 | -- | -- |
|
VRNA
Verona Pharma PLC
|
47.91% | -1.186 | 5.1% | 12.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IMCR
Immunocore Holdings PLC
|
$79.8M | -$8.5M | -7.28% | -12.92% | 12.3% | $20.3M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
VRNA
Verona Pharma PLC
|
$5.1M | -$39.1M | -55.17% | -74.15% | -583.75% | -$62.7M |
Immunocore Holdings PLC vs. Competitors
-
Which has Higher Returns IMCR or ADAP?
Adaptimmune Therapeutics PLC has a net margin of 10.89% compared to Immunocore Holdings PLC's net margin of -43.07%. Immunocore Holdings PLC's return on equity of -12.92% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital IMCRImmunocore Holdings PLC99.44% $0.17 $816.5M ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About IMCR or ADAP?
Immunocore Holdings PLC has a consensus price target of $66.54, signalling upside risk potential of 109.96%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 249.2%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Immunocore Holdings PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Immunocore Holdings PLC.
Company Buy Ratings Hold Ratings Sell Ratings IMCRImmunocore Holdings PLC7 1 1 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is IMCR or ADAP More Risky?
Immunocore Holdings PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.236, suggesting its more volatile than the S&P 500 by 123.631%.
-
Which is a Better Dividend Stock IMCR or ADAP?
Immunocore Holdings PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunocore Holdings PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCR or ADAP?
Immunocore Holdings PLC quarterly revenues are $80.2M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Immunocore Holdings PLC's net income of $8.7M is higher than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Immunocore Holdings PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunocore Holdings PLC is 5.10x versus 0.91x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCRImmunocore Holdings PLC5.10x -- $80.2M $8.7M ADAPAdaptimmune Therapeutics PLC0.91x -- $40.9M -$17.6M
-
Which has Higher Returns IMCR or AUTL?
Autolus Therapeutics PLC has a net margin of 10.89% compared to Immunocore Holdings PLC's net margin of -522.15%. Immunocore Holdings PLC's return on equity of -12.92% beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital IMCRImmunocore Holdings PLC99.44% $0.17 $816.5M AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About IMCR or AUTL?
Immunocore Holdings PLC has a consensus price target of $66.54, signalling upside risk potential of 109.96%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.45 which suggests that it could grow by 289.93%. Given that Autolus Therapeutics PLC has higher upside potential than Immunocore Holdings PLC, analysts believe Autolus Therapeutics PLC is more attractive than Immunocore Holdings PLC.
Company Buy Ratings Hold Ratings Sell Ratings IMCRImmunocore Holdings PLC7 1 1 AUTLAutolus Therapeutics PLC8 0 0 -
Is IMCR or AUTL More Risky?
Immunocore Holdings PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.049, suggesting its more volatile than the S&P 500 by 104.921%.
-
Which is a Better Dividend Stock IMCR or AUTL?
Immunocore Holdings PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunocore Holdings PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCR or AUTL?
Immunocore Holdings PLC quarterly revenues are $80.2M, which are larger than Autolus Therapeutics PLC quarterly revenues of $10.1M. Immunocore Holdings PLC's net income of $8.7M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Immunocore Holdings PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunocore Holdings PLC is 5.10x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCRImmunocore Holdings PLC5.10x -- $80.2M $8.7M AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns IMCR or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of 10.89% compared to Immunocore Holdings PLC's net margin of --. Immunocore Holdings PLC's return on equity of -12.92% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital IMCRImmunocore Holdings PLC99.44% $0.17 $816.5M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About IMCR or BDRX?
Immunocore Holdings PLC has a consensus price target of $66.54, signalling upside risk potential of 109.96%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 299.36%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Immunocore Holdings PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Immunocore Holdings PLC.
Company Buy Ratings Hold Ratings Sell Ratings IMCRImmunocore Holdings PLC7 1 1 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is IMCR or BDRX More Risky?
Immunocore Holdings PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.046%.
-
Which is a Better Dividend Stock IMCR or BDRX?
Immunocore Holdings PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunocore Holdings PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCR or BDRX?
Immunocore Holdings PLC quarterly revenues are $80.2M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Immunocore Holdings PLC's net income of $8.7M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Immunocore Holdings PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunocore Holdings PLC is 5.10x versus 4.06x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCRImmunocore Holdings PLC5.10x -- $80.2M $8.7M BDRXBiodexa Pharmaceuticals PLC4.06x -- -- --
-
Which has Higher Returns IMCR or NCNA?
NuCana PLC has a net margin of 10.89% compared to Immunocore Holdings PLC's net margin of --. Immunocore Holdings PLC's return on equity of -12.92% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMCRImmunocore Holdings PLC99.44% $0.17 $816.5M NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About IMCR or NCNA?
Immunocore Holdings PLC has a consensus price target of $66.54, signalling upside risk potential of 109.96%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 4823.66%. Given that NuCana PLC has higher upside potential than Immunocore Holdings PLC, analysts believe NuCana PLC is more attractive than Immunocore Holdings PLC.
Company Buy Ratings Hold Ratings Sell Ratings IMCRImmunocore Holdings PLC7 1 1 NCNANuCana PLC1 2 0 -
Is IMCR or NCNA More Risky?
Immunocore Holdings PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.67%.
-
Which is a Better Dividend Stock IMCR or NCNA?
Immunocore Holdings PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunocore Holdings PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCR or NCNA?
Immunocore Holdings PLC quarterly revenues are $80.2M, which are larger than NuCana PLC quarterly revenues of --. Immunocore Holdings PLC's net income of $8.7M is higher than NuCana PLC's net income of -$5.9M. Notably, Immunocore Holdings PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunocore Holdings PLC is 5.10x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCRImmunocore Holdings PLC5.10x -- $80.2M $8.7M NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns IMCR or VRNA?
Verona Pharma PLC has a net margin of 10.89% compared to Immunocore Holdings PLC's net margin of -763.91%. Immunocore Holdings PLC's return on equity of -12.92% beat Verona Pharma PLC's return on equity of -74.15%.
Company Gross Margin Earnings Per Share Invested Capital IMCRImmunocore Holdings PLC99.44% $0.17 $816.5M VRNAVerona Pharma PLC90.35% -$0.56 $250.5M -
What do Analysts Say About IMCR or VRNA?
Immunocore Holdings PLC has a consensus price target of $66.54, signalling upside risk potential of 109.96%. On the other hand Verona Pharma PLC has an analysts' consensus of $47.29 which suggests that it could grow by 1.49%. Given that Immunocore Holdings PLC has higher upside potential than Verona Pharma PLC, analysts believe Immunocore Holdings PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings IMCRImmunocore Holdings PLC7 1 1 VRNAVerona Pharma PLC5 0 0 -
Is IMCR or VRNA More Risky?
Immunocore Holdings PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.012%.
-
Which is a Better Dividend Stock IMCR or VRNA?
Immunocore Holdings PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunocore Holdings PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCR or VRNA?
Immunocore Holdings PLC quarterly revenues are $80.2M, which are larger than Verona Pharma PLC quarterly revenues of $5.6M. Immunocore Holdings PLC's net income of $8.7M is higher than Verona Pharma PLC's net income of -$43M. Notably, Immunocore Holdings PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunocore Holdings PLC is 5.10x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCRImmunocore Holdings PLC5.10x -- $80.2M $8.7M VRNAVerona Pharma PLC-- -- $5.6M -$43M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
